Dr. Lior Shaltiel reports

CORPORATE UPDATES - NUREXONE APPOINTS MR. DAVID STOLICK TO THE BOARD OF DIRECTORS

Nurexone Biologic Inc. has appointed David Stolick to its board of directors, effective July 28, 2026. Mr. Stolick succeeds the late James (Jay) Richardson, whose leadership helped shape Nurexone during its formative years.

"Jay was much more than a director. He was a dealmaker, a trusted business adviser, our presence on the ground in Canada and a true friend of the company. He believed deeply in our technology, our team and the opportunity we are working to build. May his memory be for a blessing," said Yoram Drucker, chairman of the board of Nurexone. "We also welcome David to the board. He understands what it takes to move from innovative technology to disciplined execution and we believe his perspective will be an important addition as Nurexone continues to grow."

Mr. Stolick brings extensive finance, capital markets, merger and acquisition (M&A), and health care company leadership experience. He previously served as vice-president of finance at V-Wave Ltd., a United States-Israeli medical device company acquired by Johnson & Johnson in October, 2024. He also previously served as chief financial officer of Exalenz Bioscience and BrainStorm Cell Therapeutics, and as corporate controller at M-Systems.

"I am honoured to join Nurexone's board," said Mr. Stolick. "I look forward to contributing my financial and M&A experience to support the company's growth strategy, disciplined execution and long-term shareholder value."

Mr. Stolick holds a BA in economics and accounting from Ben-Gurion University and is a certified public accountant.

Investor awareness engagement

The company has entered into an investor awareness engagement with Cashu Technologies Pty. Ltd., an arm's-length party to the company, for retail investor awareness services for a term ending no later than Dec. 31, 2026, terminable by either party on 30 days of notice. Cashu will be paid $2,500 (U.S.) per month for a monthly investor awareness program, and, if the company elects, an additional one-time fee of between $20,000 (U.S.) and $40,000 (U.S.) for an optional one-time awareness campaign. The consideration payable to Cashu is payable solely in cash and does not include any securities of the company. To the knowledge of the company, Cashu does not have any interest, directly or indirectly, in the securities of the company, or any right or intent to acquire such an interest. The engagement remains subject to the acceptance of the TSX Venture Exchange.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt Stock Exchange-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.